A Phase 3, Randomized, Single-Blind, Multicenter Study to Evaluate the Safety of TAK-438 (10 and 20 mg Once-daily) in a 52-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE).
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Vonoprazan (Primary)
- Indications Erosive oesophagitis
- Focus Adverse reactions
- 12 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 12 Jan 2012 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.
- 19 Oct 2011 New trial record